NN, Inc. Acquires Paragon Medical

We represented NN, Inc. (Nasdaq: NNBR) in the acquisition of Paragon Medical, a private equity backed medical device manufacturer, for $375 million. Paragon Medical focuses on the orthopedic, case and tray, implant and instrument markets.

NN, Inc., a diversified industrial company combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. NN has 51 facilities in North America, Western Europe, Eastern Europe, South America and China.

This transaction was named a winner in the “Healthcare and Life Sciences Deal of the Year (Over $100MM-$1B)” category at the 17th Annual M&A Advisor Awards in 2018. It had been recognized as a Finalist, along with three other deals involving Bass, Berry & Sims, for the 2018 M&A Advisor Awards.

This deal also was recognized by Global M&A Network at the 2018 M&A Atlas Awards as the USA M&A Deal of the Year – Middle Market Segment.

You Also May Be Interested In:

  • We represented ALS Education, Inc., an education dropout prevention and recovery program, in the sale of its charter school management...
    Client Type: Private Company
  • Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers

    We served as healthcare regulatory counsel to Parthenon Capital, a growth-oriented private equity firm, in its investment in RxSense, a...
    Client Type: Private Company
  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company